Cortexin
Bovine-cortex-derived polypeptide preparation used neurologically in Russia and Eastern Europe — a Cerebrolysin parallel from the same therapeutic tradition.
At a glance
What it is: Bovine-cortex-derived polypeptide preparation used neurologically in Russia and Eastern Europe — a Cerebrolysin parallel from the same therapeutic tradition..
Primary research applications:
- Stroke recovery (Russia/CIS clinical practice)
- Pediatric neurological conditions
- Cognitive support research
Editorial summary: Cortexin is a peptide-amino-acid mixture extracted from bovine cerebral cortex, used in Russia and several Eastern European countries for neurological indications including stroke recovery, traumatic brain injury, and pediatric neurological conditions. Like Cerebrolysin, it sits in the unusual category of clinically adopted-abroad / methodologically-debated-in-the-West therapeutics. The Russian-language clinical literature is substantial; independent Western evaluation is more limited.
- Class / structure
- Polypeptide-amino-acid mixture from porcine/bovine cerebral cortex
- Half-life
- Mixture-based; component-specific
- First described
- 1980s (Soviet/Russian neuroscience research)
- Regulatory status
- Approved in Russia, Belarus, and several CIS / Eastern European countries; not FDA-approved
What is Cortexin?
Cortexin is a parenteral peptide-amino-acid mixture intended to provide neurotrophic support, used as adjunctive therapy in various neurological conditions.
Discovery and development
Cortexin emerged from Soviet-era Russian neuropeptide research alongside the broader bioregulator program that produced the Khavinson short peptides, Semax, and Selank. It is manufactured from young bovine cerebral cortex tissue, processed to yield a defined mixture of low-molecular-weight peptides, free amino acids, and neurotrophic factor analogs.
The compound has been used in Russian neurological clinical practice since the 1990s for stroke, TBI, encephalopathy, and pediatric developmental and neurological conditions. Russian-language pharmaceutical literature on Cortexin is substantial; Western-language coverage and independent evaluation are more limited.
Mechanism of action
The proposed mechanism is broadly similar to Cerebrolysin: neurotrophic-factor-like activity, modulation of glutamate-mediated excitotoxicity, antioxidant effects, and support for neuroplasticity. Mixture-based pharmacology resists clean single-target characterization; the framing in the originating literature is that multiple low-molecular-weight peptides act in concert on neuronal survival and plasticity pathways.[1]
Pharmacokinetics
Cortexin is administered intramuscularly. Plasma pharmacokinetics are necessarily complex given the mixture-based composition; functional effects are believed to be mediated through neurotrophic-factor-like activities reaching the CNS via routes still being characterized in research.
What the research shows
The peer-reviewed literature on Cortexin is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Has neurotrophic-like activity | Russian preclinical and translational literature | Promising |
| Improves stroke recovery outcomes | Russian trial literature; methodological heterogeneity | Mixed |
| Helps pediatric developmental conditions | Used clinically in Russia/CIS; Western evidence-grading limited | Mixed |
| Should be considered an FDA-approvable drug | Has not been advanced through Western regulatory pathways | Uncertain |
Reported user experiences
How the research describes administration
Cortexin is given as intramuscular injection, typically in 10-day courses, repeatable periodically. Administration is by clinicians in countries where it is approved.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Cortexin is a useful parallel to Cerebrolysin in understanding the Russian neuropeptide therapeutic tradition. The clinical experience is real and the underlying neurotrophic-factor-mimicking concept is mechanistically reasonable. The evidence-grading challenge — mixture pharmacology + Russian-language trial literature + limited independent Western replication — is the same one Cerebrolysin faces, and the appropriate stance is intellectual interest tempered by recognition of the methodological gap.
Frequently asked questions
How does Cortexin compare to Cerebrolysin?
Both are peptide-amino-acid mixtures derived from animal cerebral cortex used neurologically in the Russian/CIS clinical tradition. Cerebrolysin (Ever Pharma, Austria) has more Western-language trial coverage and broader international approval. Cortexin is more Russian-domestic in its profile.
Is Cortexin available in the US?
Not as an FDA-approved product. Some patients access it via international sources; this is outside the US regulatory framework.
References
- Skoromets AA, et al. Clinical-pharmacological substantiation of cortexin use in cerebrovascular disease. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(11):42-46. (Russian-language journal) https://pubmed.ncbi.nlm.nih.gov/?term=cortexin+brain
- Bagaev VG, et al. Use of cortexin in pediatric neurology — clinical experience review. Russian Pediatric Journal. (Russian-language clinical review) https://pubmed.ncbi.nlm.nih.gov/?term=cortexin+pediatric